Global variation in renal replacement therapy for end-stage renal disease

Nephrology Dialysis Transplantation

Volumn 26, Issue 8, 2011, Pages 2604-2610

  Caskey, Fergus J ^a,b   Kramer, Anneke ^c   Elliott, Robert F ^d   Stel, Vianda S ^c   Covic, Adrian ^e   Cusumano, Ana ^f   Geue, Claudia ^d   MacLeod, Alison M ^d   Zwinderman, Aeilko H ^c   Stengel, Benedicte ^g,h   Jager, Kitty J ^c  

^a Richard Bright Renal Unit   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

^e GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f Clínicas University Institute   (Argentina)

^g INSERM   (France)

^h UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

epidemiology; health policy; macroeconomics; renal replacement therapy

Indexed keywords

AGE; AGED; ARTICLE; CONTROLLED STUDY; DEVELOPED COUNTRY; ECONOMIC ASPECT; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH SERVICE; HEALTH STATUS; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROFIT; REIMBURSEMENT; RENAL REPLACEMENT THERAPY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEALTH EXPENDITURES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; REGISTRIES; RENAL REPLACEMENT THERAPY; YOUNG ADULT;

EID: 79957780363     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq781     Document Type: Article

References (38)

1. Levey AS, Andreoli SP, DuBose T et al. Chronic kidney disease: common, harmful, and treatable-World Kidney Day 2007. J Am Soc Nephrol 2007;18:374-378 (Pubitemid 46193301)
2. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies-an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999;14:31-41 (Pubitemid 29462212)
3. Halper T. Life and death in a welfare state: end-stage renal disease in the United Kingdom. Milbank Mem Fund Q Health Soc 1985;63:52-93
4. Attinger J, Wallis C, Delaney P. Which life should be saved? Time 22 November 1982;100-101
5. U. S. Renal Data System. USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008
6. Dor A, Pauly MV, Eichleay MA et al. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ 2007;7:73-111
7. Caskey FJ, Schober-Halstenberg HJ, Roderick PJ et al. Exploring the differences in epidemiology of treated ESRD between Germany and England and Wales. Am J Kidney Dis 2006;47:445-454 (Pubitemid 43255178)
8. Horl WH, de Alvaro F, Williams PF. Healthcare systems and end-stage renal disease (ESRD) therapies-an international review: access to ESRD treatments. Nephrol Dial Transplant 1999;14(Suppl 6):10-15 (Pubitemid 29462209)
9. Caskey FJ, Stel VS, Elliott RF et al. The EVEREST study: an international collaboration. NDT Plus 2010;3:28-36
10. World Health Organisation. The World Health Report 2000-Health Systems: Improving performance. Geneva, Switzerland: World Health Organisation; 2000
11. Tripepi G, Jager KJ, Dekker FW et al. Testing for causality and prognosis: etiological and prognostic models. Kidney Int 2008;74:1512-1515
12. Jager KJ, Zoccali C, Macleod A et al. Confounding: what it is and how to deal with it. Kidney Int 2008;73:256-260
13. Kleinbaum DG, Kupper LL, Muller KE et al. Applied Regression Analysis and Other Multivariable Methods. Pacific Grove, CA: Duxbury Press, 1998, 389-390
14. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289-300
15. Grassmann A, Gioberge S, Moeller S et al. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005;20:2587-2593 (Pubitemid 41672250)
16. White SL, Chadban SJ, Jan S et al. How can we achieve global equity in provision of renal replacement therapy? Bull World Health Organ 2008;86:229-237 (Pubitemid 351480944)
17. Kjellstrand CM, Kovithavongs C, Szabo E. On the success, cost and efficiency of modern medicine: an international comparison. J Intern Med 1998;243:3-14 (Pubitemid 28072904)
18. Slade EP, Anderson GF. The relationship between per capita income and diffusion of medical technologies. Health Policy 2001;58:1-14 (Pubitemid 32757264)
19. Bech M, Christiansen T, Dunham K et al. How Do Economic Incentives and Regulatory Factors Influence Adoption of Cardiac Technologies? Result from the TECH Project. Department of Economics, Lund University, Lund, Sweden; 2006
20. Couchoud C, Guihenneuc C, Bayer F et al. The timing of dialysis initiation affects the incidence of renal replacement therapy. Nephrol Dial Transplant 2010;25:1576-1578
21. Korevaar JC, Jansen MA, Dekker FW et al. When to initiate dialysis: effect of proposed US guidelines on survival. Lancet 2001;358:1046-1050 (Pubitemid 32925125)
22. Stel VS, Dekker FW, Ansell D et al. Residual renal function at the start of dialysis and clinical outcomes. Nephrol Dial Transplant 2009;24:3175-3182
23. Termorshuizen F, Korevaar JC, Dekker FW et al. Time trends in initiation and dose of dialysis in end-stage renal disease patients in the Netherlands. Nephrol Dial Transplant 2003;18:552-558 (Pubitemid 36305661)
24. Challah S, Wing AJ, Bauer R et al. Negative selection of patients for dialysis and transplantation in the United Kingdom. Br Med J (Clin Res Ed) 1984;288:1119-1122 (Pubitemid 14083775)
25. McKenzie JK, Moss AH, Feest TG et al. Dialysis decision making in Canada, the United Kingdom, and the United States. Am J Kidney Dis 1998;31:12-18 (Pubitemid 128719037)
26. Parry RG, Crowe A, Stevens JM et al. Referral of elderly patients with severe renal failure: questionnaire survey of physicians. BMJ 1996;313:466 (Pubitemid 26280353)
27. Sekkarie M, Cosma M, Mendelssohn D. Nonreferral and nonacceptance to dialysis by primary care physicians and nephrologists in Canada and the United States. Am J Kidney Dis 2001;38:36-41 (Pubitemid 32611756)
28. Steinhauser KE, Christakis NA, Clipp EC et al. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000;284:2476-2482
29. Grewal GS, Blake GM. Reference data for 51Cr-EDTA measurements of the glomerular filtration rate derived from live kidney donors. Nucl Med Commun 2005;26:61-65 (Pubitemid 40189626)
30. Brancati FL, Whelton PK, Randall BL et al. Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997;278:2069-2074 (Pubitemid 28016228)
31. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and endstage renal disease in men. N Engl J Med 1996;334:13-18 (Pubitemid 26012498)
32. Muntner P, Coresh J, Powe NR et al. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J Am Soc Nephrol 2003;14:1568-1577 (Pubitemid 36687058)
33. Wimmer F, Oberaigner W, Kramar R et al. Regional variability in the incidence of end-stage renal disease: an epidemiological approach. Nephrol Dial Transplant 2003;18:1562-1567 (Pubitemid 36939629)
34. International Diabetes Federation. Diabetes Atlas 2003. Brussels, UK: International Diabetes Federation; 2003
35. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053 (Pubitemid 38579764)
36. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225-232 (Pubitemid 35463925)
37. Finne P, Reunanen A, Stenman S et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005;294:1782-1787 (Pubitemid 41434624)
38. Gonzalez P. Gatekeeping versus direct-access when patient information matters. Health Econ 2010;19:730-754